Design
Review
Key result
Remnant lipoprotein particles (RLPs) may contribute to the high residual cardiovascular disease risk in patients with diabetes despite statin treatment.
Authors
Loading...
Does not support changing statin therapy in diabetes; leaves open RLPs' causal role in residual risk pending standardized quantification.
Key points are not available for this paper at this time.
Chait et al. (2020) studied this question. Remnant lipoprotein particles (RLPs) may contribute to the high residual cardiovascular disease risk in patients with diabetes despite statin treatment.